NASDAQ:JNCE - Jounce Therapeutics Stock Price, Forecast & News

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics Inc (NASDAQ:JNCE) announced its quarterly earnings data on Thursday, November, 7th. The company reported $2.90 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.24 by $0.66. The company had revenue of $119.45 million for the quarter, compared to the consensus estimate of $99.97 million. Jounce Therapeutics had a return on equity of 64.54% and a net margin of 46.11%. View Jounce Therapeutics' Earnings History.

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Jounce Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

Media stories about JNCE stock have been trending extremely positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Jounce Therapeutics earned a media sentiment score of 5.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Jounce Therapeutics.

Jounce Therapeutics saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 425,400 shares, an increase of 40.9% from the September 15th total of 302,000 shares. Based on an average daily trading volume, of 125,200 shares, the days-to-cover ratio is presently 3.4 days. Currently, 2.8% of the shares of the stock are sold short. View Jounce Therapeutics' Current Options Chain.

Some companies that are related to Jounce Therapeutics include SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Precision BioSciences (DTIL), Aerie Pharmaceuticals (AERI), Vericel (VCEL), BAVARIAN NORDIC/S (BVNRY), Atara Biotherapeutics (ATRA), Twist Bioscience (TWST), MeiraGTx (MGTX), Rubius Therapeutics (RUBY), DBV TECHNOLOGIE/S (DBVT), Cortexyme (CRTX), AVITA MED LTD/S (RCEL), Adverum Biotechnologies (ADVM) and Osiris Therapeutics (OSIR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Crispr Therapeutics (CRSP), Progenics Pharmaceuticals (PGNX), Teva Pharmaceutical Industries (TEVA), Advanced Micro Devices (AMD), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Alibaba Group (BABA).

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (1.27%), Millennium Management LLC (0.48%), Strs Ohio (0.47%), Granahan Investment Management Inc. MA (0.37%), Essex Investment Management Co. LLC (0.33%) and Russell Investments Group Ltd. (0.10%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

JNCE stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Jounce Therapeutics company stock in the last year include Hugh M Cole and Kimberlee C Drapkin. View Insider Buying and Selling for Jounce Therapeutics.

JNCE stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Essex Investment Management Co. LLC, Strs Ohio, State Street Corp, Russell Investments Group Ltd., Meeder Asset Management Inc., Tower Research Capital LLC TRC and Granahan Investment Management Inc. MA. View Insider Buying and Selling for Jounce Therapeutics.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JNCE stock can currently be purchased for approximately $7.61.

Jounce Therapeutics has a market capitalization of $252.71 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.View Additional Information About Jounce Therapeutics.

The official website for Jounce Therapeutics is http://www.jouncetx.com/.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.